Cypherpunk Invests $5M in Zcash Company ZODL

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Mar 09 2026

0mins

CYPH+2.03%

Should l Buy CYPH?

Source: PRnewswire

Investment Scale: Cypherpunk Technologies Inc. announced a $5 million investment in Zcash Open Development Lab (ZODL), marking its first technology investment outside of ZEC, demonstrating the company's strong commitment to privacy technology.
Market Impact: Led by former Electric Coin Company CEO Josh Swihart, ZODL's Zashi wallet contributed to the Orchard shielded pool's growth from approximately 1 million to 4 million ZEC in 2025, indicating robust market performance.
Strategic Synergy: This investment aligns closely with Cypherpunk's current holdings of 294,743.10 ZEC, as ZODL is expected to simplify Zcash usage, thereby driving demand for ZEC and adoption of the protocol.
Industry Outlook: Cypherpunk's investment not only strengthens its position in the privacy infrastructure sector but also combines with support from notable investors like Winklevoss Capital, signaling significant future potential for widespread adoption in the digital currency space.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CYPH?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CYPH

About CYPH

Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Cypherpunk Technologies Reports FY GAAP EPS of $0.07

Mar 17 2026seekingalpha

Earnings Performance: Cypherpunk Technologies reported a FY GAAP EPS of $0.07, indicating a modest profitability level that reflects the company's ongoing operational capacity in the digital asset sector despite challenges.
Cash Position: As of December 31, 2025, the company held $14.0 million in cash and cash equivalents, demonstrating a solid liquidity management strategy that supports future operations and potential investments.
Digital Asset Holdings: The company's ZEC treasury holdings amounted to $147.4 million as of December 31, 2025, showcasing an active positioning in the digital asset market that could facilitate capital appreciation in the future.
Financial Health Assessment: While the current EPS performance is underwhelming, the robust cash reserves and digital asset holdings provide a foundation for future growth strategies, potentially attracting investor interest in the company's long-term prospects.

Cypherpunk Technologies Reports Transformational 2025 Financial Results

Mar 16 2026PRnewswire

Financial Transformation: Cypherpunk reported a net income of $4.8 million for 2025, a significant turnaround from a net loss of $67.8 million in 2024, primarily driven by $50.4 million in unrealized gains on ZEC holdings, highlighting the company's successful pivot in digital asset management.
Reduced R&D Expenses: Research and development expenses decreased to $25.7 million in 2025 from $57.2 million in 2024, reflecting effective cost control in clinical trials and manufacturing, thereby enhancing the company's financial flexibility.
Improved Cash Flow: As of December 31, 2025, Cypherpunk had $14.0 million in cash and cash equivalents, down from the beginning of the year, but the company raised $107.6 million through financing activities, indicating positive progress in capital acquisition.
Strategic Investment Initiatives: The company made a $5 million strategic investment in Zcash Open Development Lab, further solidifying its market position in privacy technology and promoting the adoption of Zcash, demonstrating a strategic vision for future growth.